Last reviewed · How we verify
HBV-MPL vaccine
HBV-MPL vaccine stimulates immune response against hepatitis B virus by combining hepatitis B surface antigen with MPL (monophosphoryl lipid A), an adjuvant that enhances T-cell and B-cell activation.
HBV-MPL vaccine stimulates immune response against hepatitis B virus by combining hepatitis B surface antigen with MPL (monophosphoryl lipid A), an adjuvant that enhances T-cell and B-cell activation. Used for Prevention of hepatitis B infection in adults.
At a glance
| Generic name | HBV-MPL vaccine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Recombinant hepatitis B vaccine with adjuvant |
| Target | Hepatitis B surface antigen (HBsAg); TLR4 (via MPL adjuvant) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine presents HBsAg to the immune system while MPL acts as a toll-like receptor 4 agonist to boost innate immune signaling, promoting stronger and more durable antibody and cellular immune responses against hepatitis B. This combination approach aims to improve immunogenicity compared to non-adjuvanted HBV vaccines, particularly in populations with weaker baseline immune responses such as older adults or immunocompromised individuals.
Approved indications
- Prevention of hepatitis B infection in adults
Common side effects
- Injection site pain or erythema
- Fatigue
- Myalgia
- Headache
Key clinical trials
- Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali (PHASE1)
- A Pilot Clinical Study of PET Scanning in Evaluation of Vaccine Reactogenicity (NA)
- Immunogenicity and Safety of an Adjuvanted HBV Vaccine Compared to Engerix™-B, in a Non-responder Population ≥ 15y (PHASE3)
- Consistency of 3 Consecutive Lots of a Novel HBV Vaccine With Single-blind Safety Evaluation Using Engerix™-B as Control (PHASE3)
- Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Healthy Volunteers Positive for the HLA-DQ2 Genotype (PHASE3)
- Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Pre-liver Transplant Patients 18 Years of Age (PHASE3)
- Evaluation of Immunogenicity, Reactogenicity and Safety of HBV-MPL Vaccine vs Engerix™-B, in Haemodialysis Patients (PHASE1)
- Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 18-40 y (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HBV-MPL vaccine CI brief — competitive landscape report
- HBV-MPL vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI